脑电生物反馈合并艾司西酞普兰治疗老年广泛性焦虑障碍的对照研究  

Clinical Research on the EEG Biofeedback and Escitalopram for Geriatric Generalized Anxiety Disorder in the Elderly

作　　者：唐颖[1,2] 宋丹[1,2] 田悦[1,2] 程奥博 

机构地区：[1]华北理工大学附属开滦精神卫生中心,河北唐山063001 [2]华北理工大学精神卫生研究所

出　　处：《中国健康心理学杂志》2016年第5期655-657,共3页China Journal of Health Psychology

摘　　要：目的:观察脑电生物反馈联合艾司西酞普兰治疗老年广泛性焦虑障碍的疗效和安全性。方法:选择45例老年广泛性焦虑障碍患者随机分为两组,研究组给予脑电生物反馈联合艾司西酞普兰治疗,对照组仅给予艾司西酞普兰治疗,均治疗8周。分别于治疗前及治疗后1,2,4,6,8周时应用汉密尔顿焦虑量表(HAMA)评估其疗效;应用副作用量表(TESS)评估其不良反应。结果:在治疗第1周、第2周两组HAMA总分比较有显著性差异(t=-3.40,-3.65;P<0.05),治疗组分数低于对照组,在第4周到第8周两组HAMA两组总分比较无显著性差异,在治疗第1周、第2周研究组躯体性焦虑因子分明显低于对照组(t=-2.05,-2.72;P<0.05),精神性焦虑因子两组比较无显著性差异(P>0.05);研究组有效率为82.6%,对照组有效率为81.8%,两组有效率比较无显著性差异;两组间TESS评分比较无明显差异性。结论:脑电生物反馈联合艾司西酞普兰治疗广泛性焦虑障碍起效更快,尤其对躯体焦虑的改善更快,并且不增加不良反应。Objective：To investigate the efficacy and safety of treatment of EEG biofeedback and escitalopram for geriatric generalized anxiety disorder in the elderly.Methods：A total of 45 older patients with generalized anxiety dis-order were randomly assigned to two groups for 8 weeks treatment,one group used the EEG biofeedback with es-citalopram,the other used the escitalopram only.The HAMA and TESS were evaluated at baseline and 1,2,4,6,8 week after changed.Results：After 1-week and 2-week treatment,there were significant difference in the scores of HAMD between the two groups（t=-3.40,-3.65;P〈0.05）;After 4-week,6-week and 8-week treatment,there were no significant differences in the scores of HAMD between the two groups.After 1-week and 2-week treat-ment,the difference of somatoform anxiety scores between the two groups were significant（t=-2.05,-2.72;P〈0.05）;The effective rate of study group was 82.6% while the control group＇s effective rate was 81.8%.There was no significant difference between the two groups.There was no significant difference in the scores of TESS between the two groups.Conclusion：EEG biofeedback and escitalopram in the treatment of older patients with generalized anxiety disorder takes effect faster and is safe.

关 键 词：脑电生物反馈 艾司西酞普兰 老年广泛性焦虑障碍 疗效 安全性 

分 类 号：R749.053[医药卫生—神经病学与精神病学]